Atea Pharmaceuticals

Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases. The company is currently focused on developing orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) and hepatitis E virus (HEV). Its lead regimen, bemnifosbuvir/ruzavir, is advancing in a global Phase 3 development program for HCV, and in July 2026, the company announced that its Phase 3 trial C-BEYOND achieved its primary and secondary endpoints.

Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases. The company is focused on developing orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) and hepatitis E virus (HEV). Its lead regimen, bemnifosbuvir/ruzavir, is advancing in a global Phase 3 development program for HCV. In July 2026, Atea announced that its Phase 3 trial C-BEYOND achieved its primary and secondary endpoints.

• 2020.10.22

  Roche and Atea announce AT-527 collaboration[6]罗氏与Atea宣布合作开发AT-527selectscience.net

  Roche and Atea Pharmaceuticals announced a collaboration to develop, manufacture, and distribute AT-527, an investigational oral antiviral being studied for COVID-19. Roche is responsible for distribution outside the United States; Atea is responsible for U.S. distribution, with an option to request Genentech’s support.

Read more

1. 1Home - Atea Pharmaceuticalsateapharma.com
2. 2About Us - Atea Pharmaceuticalsateapharma.com
3. 3Hepatitis C - Atea Pharmaceuticalsateapharma.com
4. 4Careers - Atea Pharmaceuticalsateapharma.com
5. 5Atea Pharmaceuticals (United States)wikidata.org
6. 6罗氏与Atea宣布合作开发AT-527selectscience.net